Literature DB >> 30251929

Pancreatic Cancer CT: Prediction of Resectability according to NCCN Criteria.

Seung Baek Hong1, Seung Soo Lee1, Jin Hee Kim1, Hyoung Jung Kim1, Jae Ho Byun1, Seung Mo Hong1, Ki-Byung Song1, Song Cheol Kim1.   

Abstract

Purpose To evaluate the diagnostic performance of CT in the determination of pancreatic cancer resectability according to the National Comprehensive Cancer Network (NCCN) criteria to predict R0 resection. Materials and Methods Structured reports of pancreatic CT clinically prepared by board-certified abdominal radiologists from January 2014 to March 2017 were retrospectively reviewed to assess resectability (resectable, borderline resectable, or unresectable) according to NCCN criteria (version 1.2017) in 616 patients (369 men, 247 women; mean age, 63 years ± 10 [standard deviation]) with pancreatic cancer. Negative resection margin (R0) rates were assessed based on CT resectability status in patients who underwent upfront surgery. R0 resection-associated factors were identified by using logistic regression analysis. Results In 371 patients who underwent surgery, R0 resection rates were 73% (171 of 235), 55% (57 of 104), and 16% (five of 32) for resectable, borderline resectable, and unresectable disease, respectively (P < .001). At multivariable analysis, tumor diameter larger than 4 cm (P < .001) and abutment to the portomesenteric vein (P < .001) were significantly associated with margin-positive resection in patients with resectable disease at CT. R0 resection rates were 80% (123 of 154) for resectable disease without portomesenteric vein abutment, 59% (48 of 81) for resectable disease with portomesenteric vein abutment, 83% (57 of 69) for resectable disease 2 cm or smaller, and 29% (five of 17) for tumors larger than 4 cm. Conclusion CT resectability is used to stratify patients with pancreatic cancer according to the possibility of R0 resection. Larger tumor size and tumor abutment to the portomesenteric vein are associated with margin-positive resection in patients with resectable pancreatic cancer. © RSNA, 2018 Online supplemental material is available for this article. See also the editorial by Fowler in this issue.

Entities:  

Mesh:

Year:  2018        PMID: 30251929     DOI: 10.1148/radiol.2018180628

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  20 in total

1.  Performance of CT-based radiomics in diagnosis of superior mesenteric vein resection margin in patients with pancreatic head cancer.

Authors:  Yun Bian; Hui Jiang; Chao Ma; Kai Cao; Xu Fang; Jing Li; Li Wang; Jianming Zheng; Jianping Lu
Journal:  Abdom Radiol (NY)       Date:  2020-03

Review 2.  Use of imaging as staging and surgical planning for pancreatic surgery.

Authors:  Andrew Hieu Nguyen; Laleh G Melstrom
Journal:  Hepatobiliary Surg Nutr       Date:  2020-10       Impact factor: 7.293

3.  Prognostic value of preoperative enhanced computed tomography as a quantitative imaging biomarker in pancreatic cancer.

Authors:  Jian-Feng Gao; Yu Pan; Xian-Chao Lin; Feng-Chun Lu; Ding-Shen Qiu; Jun-Jun Liu; He-Guang Huang
Journal:  World J Gastroenterol       Date:  2022-06-14       Impact factor: 5.374

4.  Clinical Significance of Neoadjuvant Chemotherapy With Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma.

Authors:  Takashi Suzuki; Shozo Mori; Takayuki Shimizu; Kazuma Tago; Nobuhiro Harada; Kyung-Hwa Park; Yuhki Sakuraoka; Takayuki Shiraki; Yukihiro Iso; Taku Aoki; Keiichi Kubota
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

5.  [18F]FMISO PET/CT as a preoperative prognostic factor in patients with pancreatic cancer.

Authors:  Tomohiko Yamane; Masayasu Aikawa; Masanori Yasuda; Kenji Fukushima; Akira Seto; Koujun Okamoto; Isamu Koyama; Ichiei Kuji
Journal:  EJNMMI Res       Date:  2019-05-09       Impact factor: 3.138

Review 6.  The Role of Imaging in Current Treatment Strategies for Pancreatic Adenocarcinoma.

Authors:  Hyungjin Rhee; Mi Suk Park
Journal:  Korean J Radiol       Date:  2020-08-28       Impact factor: 3.500

7.  Preoperative CT predictors of survival in patients with pancreatic ductal adenocarcinoma undergoing curative intent surgery.

Authors:  Shannan M Dickinson; Caitlin A McIntyre; Juliana B Schilsky; Kate A Harrington; Scott R Gerst; Jessica R Flynn; Mithat Gonen; Marinela Capanu; Winston Wong; Sharon Lawrence; Peter J Allen; Eileen M O'Reilly; William R Jarnagin; Michael I D'Angelica; Vinod P Balachandran; Jeffrey A Drebin; T Peter Kingham; Amber L Simpson; Richard K Do
Journal:  Abdom Radiol (NY)       Date:  2020-09-28

8.  Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection.

Authors:  Adam R Wolfe; Dhivya Prabhakar; Vedat O Yildiz; Jordan M Cloyd; Mary Dillhoff; Laith Abushahin; Dayssy Alexandra Diaz; Eric D Miller; Wei Chen; Wendy L Frankel; Anne Noonan; Terence M Williams
Journal:  Cancer Med       Date:  2020-05-16       Impact factor: 4.452

9.  Quantifying vascular invasion in pancreatic cancer-a contrast CT based method for surgical resectability evaluation.

Authors:  Yi Lao; John David; Zhaoyang Fan; Shelly Bian; Almon Shiu; Eric L Chang; Ke Sheng; Wensha Yang; Richard Tuli
Journal:  Phys Med Biol       Date:  2020-06-01       Impact factor: 3.609

10.  A New Score to Predict the Resectability of Pancreatic Adenocarcinoma: The BACAP Score.

Authors:  Charlotte Maulat; Cindy Canivet; Célia Touraine; Sophie Gourgou; Bertrand Napoleon; Laurent Palazzo; Nicolas Flori; Guillaume Piessen; Pierre Guibert; Stéphanie Truant; Eric Assenat; Louis Buscail; Barbara Bournet; Fabrice Muscari
Journal:  Cancers (Basel)       Date:  2020-03-25       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.